From: Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Combination therapy | Type of cancer | Phase | N | Outcome (most relevant findings) | Literature |
---|---|---|---|---|---|
None | Acute myeloid leukemia | II | 37 | 1 Response (group 3 × 200 mg) | Schäfer et al. (2009) |
None | Follicular (FL) and mantle cell lymphoma (MCL) | I | 10 | 40% Response; 2CRu, 1PR (FL); 1CRu (MCL) | Watanabe et al. (2010) |
None | Solid tumors | I | 18 | MTD was not reached | Fujiwara et al. (2009) |
None | Advanced prostate cancer | II | 27 | 2SD; all patients off therapy before 6Â months | Bradley et al. (2009) |
None | Recurrent glioblastoma multiforme | II | 52 | 9 Progression-free after 6Â month | Galanis et al. (2009) |
Bortezomib | Relapsed and refractory multiple myeloma | I | 23 | 42% Response rate; 3PR | Badros et al. (2009) |
Peg-Lip-Doxorubicin, Bortezomib | Relapsed/refractory Multiple Myeloma | I | 7 | 1CR, 1vgPR, 4PR | Voorhees et al. (2009)a |
Idarubicin, Cytarabine | Acute myelogenous leukemia | II | 45 | Response rate 80%; 35CR, 1CRP | Garcia-Manero et al. (2009)a |
Lenalidomide, Dexamethasone | Relapsed/refractory multiple myeloma | I | 25 | Response rate 64%; 1CR, 1nCR, 2vgPR, 8PR, 4MR, 5SD | Siegel et al. (2009)a |
Decitabine | Acute myelogenous leukemia/myelodysplastic syndrome | I | MDS n = 11 AML n = 50 | MDS: 2CR, 1PR, 1HI, 7SD AML: 7CR, 4CRi, 2PR, 3HI, 26SD | Kirschbaum et al. (2009)a |
Rituximab, Ifosphamide, Carboplatin, Etoposide (ICE) | Relapsed/refractory lymphoid malignancies, untreated T-cell/mantle cell lymphoma | I | 14 | 1CR, 2CRu, 9PR, 1SD | Budde et al. (2009)a |
pelvic palliative radiotherapy | Gastrointestinal carcinoma | I | 16 | MTD = 300 mg once daily | Ree et al. (2010) |
5-FU, Leucovorin | Metastatic colorectal cancer | I/II | 10 | No MTD could be established; 2SD; study was closed | Wilson et al. (2010) |
Carboplatin, Paclitaxel | Advanced stage NSCLC | II | 94 | 34% Response with Vorinostat vs 12.5% with Placebo | Ramalingam et al. (2010) |
Doxorubicin | Solid tumors | I | 24 | MTD = 800 mg; 2PR (breast, prostate cancer); 2SD (melanoma) | Munster et al. (2009a) |
5-FU, Leucovorin, Oxaliplatin | Refractory colorectal cancer | I | 21 | MTD = 300 mg twice daily | Fakih et al. (2009) |
Tamoxifen | Advanced breast cancer | II | 29 | 6 Response; 3SD | Munster et al. (2009c)a |
Bortezomib | Refractory solid tumors | I | 29 | MTD 300Â mg BID | Ninan et al. (2009)a |
Gemcitabine, Cisplatinum | Advanced NSCLC | I | 28 | 9PR, 8SD | Trédaniel et al. (2009)a |
Erlotinib | NSCLC | I | 13 | 6SD | Reguart et al. (2009)a |
Docetaxel | Solid tumors | I | 12 | No response | Schneider et al. (2009)a |